Skip to main content
Erschienen in: Cancer Causes & Control 1/2012

01.01.2012 | Original paper

Reproductive factors and lymphoid neoplasms in Europe: findings from the EpiLymph case–control study

verfasst von: Laura Costas, Delphine Casabonne, Yolanda Benavente, Nikolaus Becker, Paolo Boffetta, Paul Brennan, Pierluigi Cocco, Lenka Foretova, Marc Maynadié, Anthony Staines, Eleanor Kane, Alexandra Nieters, Silvia de Sanjosé

Erschienen in: Cancer Causes & Control | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The study of lymphomagenesis has rarely focused on hormonal factors. Higher incidence rates are observed for many lymphoma subtypes in men compared with women suggesting an underlying association. Our goal was to investigate the association between reproductive factors and lymphomas.

Methods

The Epilymph study is a multicenter case–control study carried out in six European countries from 1998 to 2004. Female cases of mature T-cell neoplasms (n = 52), Hodgkin lymphoma (n = 147), and mature B-cell neoplasms (n = 795), including its common subtypes, and their respective controls (n = 1,141) frequency matched by age, gender, and center were considered.

Results

An odds reduction of 29% (95% CI −46 to −6%) was observed for mature T-cell neoplasms for each child increase among parous women and of 13% (95% CI −19 to −7%) for mature B-cell neoplasms; while no association was observed for Hodgkin lymphoma. By B-cell neoplasm subtypes, these associations were found for chronic lymphocytic leukemia/small lymphocytic lymphoma (−21%, 95% CI −31 to −9%) and diffuse large B-cell lymphoma (DLBCL; −14%; 95% CI −23 to −3%). Overall, no associations were observed with age at first and last pregnancy, and ever use of hormonal contraceptives and lymphoma. Higher odds ratios for a short-term use of hormonal contraceptives (<5 years), but not for a long-term use, were observed for mature B-cell neoplasms, DLBCL, and follicular lymphoma compared with never use.

Conclusion

These data support the hypothesis that increased parity confers a protective effect against lymphoma. Less clearly, our results also indicate that hormonal contraceptives could play a role.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A et al (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 148(5):739–753PubMedCrossRef Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A et al (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 148(5):739–753PubMedCrossRef
2.
Zurück zum Zitat Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S et al (2010) Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly 140(13–14):187–201PubMed Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S et al (2010) Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly 140(13–14):187–201PubMed
3.
Zurück zum Zitat Prescott J, Lu Y, Chang ET, Sullivan-Halley J, Henderson KD, Clarke CA et al (2009) Reproductive factors and non-Hodgkin lymphoma risk in the California Teachers Study. PLoS One 4(12):e8135PubMedCrossRef Prescott J, Lu Y, Chang ET, Sullivan-Halley J, Henderson KD, Clarke CA et al (2009) Reproductive factors and non-Hodgkin lymphoma risk in the California Teachers Study. PLoS One 4(12):e8135PubMedCrossRef
4.
Zurück zum Zitat Lee JS, Bracci PM, Holly EA (2008) Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol 168(3):278–288PubMedCrossRef Lee JS, Bracci PM, Holly EA (2008) Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol 168(3):278–288PubMedCrossRef
5.
Zurück zum Zitat Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang B et al (2004) Menstrual and reproductive factors and risk of non-Hodgkin’s lymphoma among Connecticut women. Am J Epidemiol 160(8):766–773PubMedCrossRef Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang B et al (2004) Menstrual and reproductive factors and risk of non-Hodgkin’s lymphoma among Connecticut women. Am J Epidemiol 160(8):766–773PubMedCrossRef
6.
Zurück zum Zitat Kravdal O, Hansen S (1993) Hodgkin’s disease: the protective effect of childbearing. Int J Cancer 55(6):909–914PubMedCrossRef Kravdal O, Hansen S (1993) Hodgkin’s disease: the protective effect of childbearing. Int J Cancer 55(6):909–914PubMedCrossRef
7.
Zurück zum Zitat Zahm SH, Hoover RN, Fraumeni JF Jr (1995) Hodgkin’s disease and parity. Int J Cancer 62(3):362–363PubMedCrossRef Zahm SH, Hoover RN, Fraumeni JF Jr (1995) Hodgkin’s disease and parity. Int J Cancer 62(3):362–363PubMedCrossRef
8.
Zurück zum Zitat Cerhan JR, Habermann TM, Vachon CM, Putnam SD, Zheng W, Potter JD et al (2002) Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women’s health study (United States). Cancer Causes Control 13(2):131–136PubMedCrossRef Cerhan JR, Habermann TM, Vachon CM, Putnam SD, Zheng W, Potter JD et al (2002) Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women’s health study (United States). Cancer Causes Control 13(2):131–136PubMedCrossRef
9.
Zurück zum Zitat Adami HO, Tsaih S, Lambe M, Hsieh C, Adami J, Trichopoulos D et al (1997) Pregnancy and risk of non-Hodgkin’s lymphoma: a prospective study. Int J Cancer 70(2):155–158PubMedCrossRef Adami HO, Tsaih S, Lambe M, Hsieh C, Adami J, Trichopoulos D et al (1997) Pregnancy and risk of non-Hodgkin’s lymphoma: a prospective study. Int J Cancer 70(2):155–158PubMedCrossRef
10.
Zurück zum Zitat Morton LM, Wang SS, Richesson DA, Schatzkin A, Hollenbeck AR, Lacey JV Jr (2009) Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. Int J Cancer 124(11):2737–2743PubMedCrossRef Morton LM, Wang SS, Richesson DA, Schatzkin A, Hollenbeck AR, Lacey JV Jr (2009) Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. Int J Cancer 124(11):2737–2743PubMedCrossRef
11.
Zurück zum Zitat Mildon KH, Ansell P, Roman E, Kane EV (2010) Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study. Cancer Causes Control 21(12):2079–2083 Mildon KH, Ansell P, Roman E, Kane EV (2010) Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study. Cancer Causes Control 21(12):2079–2083
12.
Zurück zum Zitat Nelson RA, Levine AM, Bernstein L (2001) Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin’s lymphoma in women. J Clin Oncol 19(5):1381–1387PubMed Nelson RA, Levine AM, Bernstein L (2001) Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin’s lymphoma in women. J Clin Oncol 19(5):1381–1387PubMed
13.
Zurück zum Zitat Tavani A, Pregnolato A, La Vecchia C, Franceschi S (1997) A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 21(9):885–888PubMedCrossRef Tavani A, Pregnolato A, La Vecchia C, Franceschi S (1997) A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 21(9):885–888PubMedCrossRef
14.
Zurück zum Zitat Zwitter M, Zakelj MP, Kosmelj K (1996) A case-control study of Hodgkin’s disease and pregnancy. Br J Cancer 73(2):246–251PubMedCrossRef Zwitter M, Zakelj MP, Kosmelj K (1996) A case-control study of Hodgkin’s disease and pregnancy. Br J Cancer 73(2):246–251PubMedCrossRef
15.
Zurück zum Zitat Lambe M, Hsieh CC, Tsaih SW, Adami J, Glimelius B, Adami HO (1998) Childbearing and the risk of Hodgkin’s disease. Cancer Epidemiol Biomarkers Prev 7(9):831–834PubMed Lambe M, Hsieh CC, Tsaih SW, Adami J, Glimelius B, Adami HO (1998) Childbearing and the risk of Hodgkin’s disease. Cancer Epidemiol Biomarkers Prev 7(9):831–834PubMed
16.
Zurück zum Zitat Schiff D, Suman VJ, Yang P, Rocca WA, O’Neill BP (1998) Risk factors for primary central nervous system lymphoma: a case-control study. Cancer 82(5):975–982PubMedCrossRef Schiff D, Suman VJ, Yang P, Rocca WA, O’Neill BP (1998) Risk factors for primary central nervous system lymphoma: a case-control study. Cancer 82(5):975–982PubMedCrossRef
17.
Zurück zum Zitat Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM et al (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15(4):419–428PubMedCrossRef Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM et al (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15(4):419–428PubMedCrossRef
18.
Zurück zum Zitat Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) No increased risk of non-Hodgkin’s lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 14(7):639–644PubMedCrossRef Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) No increased risk of non-Hodgkin’s lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 14(7):639–644PubMedCrossRef
19.
Zurück zum Zitat Cerhan JR, Wallace RB, Folsom AR, Potter JD, Sellers TA, Zheng W et al (1997) Medical history risk factors for non-Hodgkin’s lymphoma in older women. J Natl Cancer Inst 89(4):314–318PubMed Cerhan JR, Wallace RB, Folsom AR, Potter JD, Sellers TA, Zheng W et al (1997) Medical history risk factors for non-Hodgkin’s lymphoma in older women. J Natl Cancer Inst 89(4):314–318PubMed
20.
Zurück zum Zitat Lu Y, Wang SS, Sullivan-Halley J, Chang ET, Clarke CA, Henderson KD et al (2011) Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study. Int J Cancer 129(4):974–982 Lu Y, Wang SS, Sullivan-Halley J, Chang ET, Clarke CA, Henderson KD et al (2011) Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study. Int J Cancer 129(4):974–982
21.
Zurück zum Zitat Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF (2003) Reproductive factors in Hodgkin’s disease in women. Am J Epidemiol 158(6):553–563PubMedCrossRef Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF (2003) Reproductive factors in Hodgkin’s disease in women. Am J Epidemiol 158(6):553–563PubMedCrossRef
22.
Zurück zum Zitat de Sanjose S, Benavente Y, Nieters A, Foretova L, Maynadie M, Cocco PL et al (2006) Association between personal use of hair dyes and lymphoid neoplasms in Europe. Am J Epidemiol 164(1):47–55PubMedCrossRef de Sanjose S, Benavente Y, Nieters A, Foretova L, Maynadie M, Cocco PL et al (2006) Association between personal use of hair dyes and lymphoid neoplasms in Europe. Am J Epidemiol 164(1):47–55PubMedCrossRef
23.
Zurück zum Zitat Grulich AE, Vajdic CM, Falster MO, Kane E, Smedby KE, Bracci PM et al (2010) Birth order and risk of non-hodgkin lymphoma—true association or bias? Am J Epidemiol 172(6):621–630PubMedCrossRef Grulich AE, Vajdic CM, Falster MO, Kane E, Smedby KE, Bracci PM et al (2010) Birth order and risk of non-hodgkin lymphoma—true association or bias? Am J Epidemiol 172(6):621–630PubMedCrossRef
24.
Zurück zum Zitat Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM et al (2010) InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 116(20):e90–e98PubMedCrossRef Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM et al (2010) InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 116(20):e90–e98PubMedCrossRef
25.
Zurück zum Zitat Swerdlow S, Campo E, Harris N (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon Swerdlow S, Campo E, Harris N (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
26.
Zurück zum Zitat IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2007) Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 91:1–528 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2007) Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum 91:1–528
27.
Zurück zum Zitat Frisch M, Pedersen BV, Wohlfahrt J, Hjalgrim H, Biggar RJ (2006) Reproductive patterns and non-Hodgkin lymphoma risk in Danish women and men. Eur J Epidemiol 21(9):673–679PubMedCrossRef Frisch M, Pedersen BV, Wohlfahrt J, Hjalgrim H, Biggar RJ (2006) Reproductive patterns and non-Hodgkin lymphoma risk in Danish women and men. Eur J Epidemiol 21(9):673–679PubMedCrossRef
28.
Zurück zum Zitat Kravdal O, Hansen S (1996) The importance of childbearing for Hodgkin’s disease: new evidence from incidence and mortality models. Int J Epidemiol 25(4):737–743PubMedCrossRef Kravdal O, Hansen S (1996) The importance of childbearing for Hodgkin’s disease: new evidence from incidence and mortality models. Int J Epidemiol 25(4):737–743PubMedCrossRef
29.
Zurück zum Zitat Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S et al (2008) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 112(13):5150–5160PubMedCrossRef Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S et al (2008) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 112(13):5150–5160PubMedCrossRef
30.
Zurück zum Zitat Cutolo M, Brizzolara R, Atzeni F, Capellino S, Straub RH, Puttini PC (2010) The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann N Y Acad Sci 1193:36–42PubMedCrossRef Cutolo M, Brizzolara R, Atzeni F, Capellino S, Straub RH, Puttini PC (2010) The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann N Y Acad Sci 1193:36–42PubMedCrossRef
31.
Zurück zum Zitat Klinger G, Graser T, Mellinger U, Moore C, Vogelsang H, Groh A et al (2000) A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system. Gynecol Endocrinol 14(1):15–24PubMedCrossRef Klinger G, Graser T, Mellinger U, Moore C, Vogelsang H, Groh A et al (2000) A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system. Gynecol Endocrinol 14(1):15–24PubMedCrossRef
32.
Zurück zum Zitat Gilmore W, Weiner LP, Correale J (1997) Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 158(1):446–451PubMed Gilmore W, Weiner LP, Correale J (1997) Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 158(1):446–451PubMed
33.
Zurück zum Zitat Bouman A, Heineman MJ, Faas MM (2005) Sex hormones and the immune response in humans. Hum Reprod 11(4):411–423CrossRef Bouman A, Heineman MJ, Faas MM (2005) Sex hormones and the immune response in humans. Hum Reprod 11(4):411–423CrossRef
34.
Zurück zum Zitat Szekeres-Bartho J, Halasz M, Palkovics T (2009) Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol 83(1–2):60–64PubMedCrossRef Szekeres-Bartho J, Halasz M, Palkovics T (2009) Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol 83(1–2):60–64PubMedCrossRef
35.
Zurück zum Zitat Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M et al (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107(10):4101–4108PubMedCrossRef Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M et al (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107(10):4101–4108PubMedCrossRef
36.
Zurück zum Zitat Lin SS, Glaser SL, Stewart SL (2002) Reliability of self-reported reproductive factors and childhood social class indicators in a case-control study in women. Ann Epidemiol 12(4):242–247PubMedCrossRef Lin SS, Glaser SL, Stewart SL (2002) Reliability of self-reported reproductive factors and childhood social class indicators in a case-control study in women. Ann Epidemiol 12(4):242–247PubMedCrossRef
37.
Zurück zum Zitat Norell SE, Boethius G, Persson I (1998) Oral contraceptive use: interview data versus pharmacy records. Int J Epidemiol 27(6):1033–1037PubMedCrossRef Norell SE, Boethius G, Persson I (1998) Oral contraceptive use: interview data versus pharmacy records. Int J Epidemiol 27(6):1033–1037PubMedCrossRef
38.
Zurück zum Zitat Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin’s lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52(19 Suppl):5510s–5515sPubMed Bernstein L, Ross RK (1992) Prior medication use and health history as risk factors for non-Hodgkin’s lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52(19 Suppl):5510s–5515sPubMed
39.
Zurück zum Zitat Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ et al (2002) Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 11(11):1466–1471PubMed Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ et al (2002) Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 11(11):1466–1471PubMed
40.
Zurück zum Zitat Kravdal O (1995) Is the relationship between childbearing and cancer incidence due to biology or lifestyle? Examples of the importance of using data on men. Int J Epidemiol 24(3):477–484PubMedCrossRef Kravdal O (1995) Is the relationship between childbearing and cancer incidence due to biology or lifestyle? Examples of the importance of using data on men. Int J Epidemiol 24(3):477–484PubMedCrossRef
Metadaten
Titel
Reproductive factors and lymphoid neoplasms in Europe: findings from the EpiLymph case–control study
verfasst von
Laura Costas
Delphine Casabonne
Yolanda Benavente
Nikolaus Becker
Paolo Boffetta
Paul Brennan
Pierluigi Cocco
Lenka Foretova
Marc Maynadié
Anthony Staines
Eleanor Kane
Alexandra Nieters
Silvia de Sanjosé
Publikationsdatum
01.01.2012
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 1/2012
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9869-6

Weitere Artikel der Ausgabe 1/2012

Cancer Causes & Control 1/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.